1Chung HC, Rha SY, Kim JH, et al. P - glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat, 1997,42 (1) : 65 72.
2Nussey F, Turner ML. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM - CSF: effect on tumour draining lymph node dendritic cells. Eur J Cancer. 2003,39(5) : 1039 - 1040.
3Sauven P. The surgical management of patients following neoadjuvant chemotherapy for locally advanced breast cancer. Eur J Cancer,2002,38(11) :2371-2374.
4Henry MK, SEva S, Aman UB, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage Ⅱ and operable stage Ⅲ breast carcinoma. Am J Surg,2001,182(4) :601 - 608.
5Lawrence G, Crawford J, Sherman F. Evaluating necadjuvant chemotherapy in breast cancer. J Clini Oncol, 2002,20 ( 12 ) : 2905- 2906.
6Pierga JY, Mouret E, Laurence V, et al. Prcgnostic factors for survival after neoadjuvant chemotherapy in operable breast cancer: the role of clinical response. Eur J Cancer, 2003, (39): 1089 - 1096.
7Ikeda T, Jinno H, Matsu A, et al. The role of neoadjuvant chemotherapy for breast cancer treament. Breast Cancer, 2002,9(1):8-14.
